200 related articles for article (PubMed ID: 18668148)
1. PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.
Jia NL; Fei EK; Ying Z; Wang HF; Wang GH
Neurosci Bull; 2008 Aug; 24(4):201-8. PubMed ID: 18668148
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
3. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
4. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
5. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
6. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
[TBL] [Abstract][Full Text] [Related]
7. PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study.
Gonsior K; Kaucher GA; Pelz P; Schumann D; Gansel M; Kuhs S; Klockgether T; Forlani S; Durr A; Hauser S; Rattay TW; Synofzik M; Hengel H; Schöls L; Rieß OH; Hübener-Schmid J
J Neurol; 2021 Apr; 268(4):1304-1315. PubMed ID: 33106888
[TBL] [Abstract][Full Text] [Related]
8. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.
Lin GY; Ma CY; Kuo LC; Hsieh BY; Wang H; Liu CS; Hsieh M
Metab Brain Dis; 2022 Aug; 37(6):2103-2120. PubMed ID: 35488942
[TBL] [Abstract][Full Text] [Related]
9. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
10. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
11. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
12. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
Abeditashi M; Weber JJ; Pereira Sena P; Velic A; Kalimeri M; Incebacak Eltemur RD; Schmidt J; Hübener-Schmid J; Hauser S; Macek B; Riess O; Schmidt T
Cell Mol Life Sci; 2022 Jul; 79(8):401. PubMed ID: 35794401
[TBL] [Abstract][Full Text] [Related]
13. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP; Herzog LK
Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
[TBL] [Abstract][Full Text] [Related]
14. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
15. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.
Durcan TM; Kontogiannea M; Thorarinsdottir T; Fallon L; Williams AJ; Djarmati A; Fantaneanu T; Paulson HL; Fon EA
Hum Mol Genet; 2011 Jan; 20(1):141-54. PubMed ID: 20940148
[TBL] [Abstract][Full Text] [Related]
16. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD.
Jana NR; Nukina N
Neurotox Res; 2004; 6(7-8):523-33. PubMed ID: 15639784
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model.
Bonanomi M; Natalello A; Visentin C; Pastori V; Penco A; Cornelli G; Colombo G; Malabarba MG; Doglia SM; Relini A; Regonesi ME; Tortora P
Hum Mol Genet; 2014 Dec; 23(24):6542-52. PubMed ID: 25030034
[TBL] [Abstract][Full Text] [Related]
18. Casein kinase 2 interacts with and phosphorylates ataxin-3.
Tao RS; Fei EK; Ying Z; Wang HF; Wang GH
Neurosci Bull; 2008 Oct; 24(5):271-7. PubMed ID: 18839019
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamine expansion accelerates the dynamics of ataxin-1 and does not result in aggregate formation.
Krol HA; Krawczyk PM; Bosch KS; Aten JA; Hol EM; Reits EA
PLoS One; 2008 Jan; 3(1):e1503. PubMed ID: 18231590
[TBL] [Abstract][Full Text] [Related]
20. The relationship between aggregation and toxicity of polyglutamine-containing ataxin-3 in the intracellular environment of Escherichia coli.
Invernizzi G; Aprile FA; Natalello A; Ghisleni A; Penco A; Relini A; Doglia SM; Tortora P; Regonesi ME
PLoS One; 2012; 7(12):e51890. PubMed ID: 23251648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
